Chiron Corporation

Aviron

Medimmune Limited

Medimmune Vaccines, Inc.

Other

Richard R Spaete

George William Kemble

Tai-An Cha

Gregory Duke

Michael Houghton

Mark J Selby

Jang Hyun Han

Carol A Pachl

Byung S Suh

Byoung J Yoo

Bernard Roizman

Winthrop Jackman

Winthrop T Jackman

Mark Prichard

Frances C Spector

A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.

Attenuation of cytomegalovirus virulence

Live, attenuated, phenotypically stable HSV-2 viruses and methods of making and using the virus are provided. Live, attenuated HSV-2 viruses are constructed using recombinant techniques and can be used in a pharmaceutical composition for prophylactic treatment of HSV-2 infections and for treatment of recurrent HSV-2 related diseases and conditions.

Methods and compositions for treatment and prevention of HSV-2 infections and conditions

A novel Human Cytomegalovirus vector system is provided. The vector system is characterized by an amplicon vector, having an HCMV derived origin and cleavage packaging signal, and a helper virus function. The vector system is capable of infecting a wide range of host cells, including human CD34hematopoietic progenitor cells. Methods, including therapeutic and prophylactic methods, for introducing heterologous polynucleotide sequences into cells using the vector system are also provided.

Large capacity viral amplicon using a minimal orilyt from human cytomegalovirus

Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for Preventing HCMV infections.

Human cytomegalovirus DNA sequences

Embodiments of the present invention feature methods and compositions for controlling the translation of viral peptides and proteins from viral nucleic acid, with particular applications to pestivirus and HCV. The methods and compositions feature control elements of the 5'UT region of the viral genome.

Methods and compositions for controlling translation of HCV proteins

Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.

Non-splicing variants of gp350/220

Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for preventing HCMV infections.

Provided are novel Toledo and Towne Human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for preventing HCMV infections.

The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.

Growing community of inventors

Belmont, CA, United States of America

Richard R Spaete